265 related articles for article (PubMed ID: 32661115)
1. Current challenges for assessing the long-term clinical benefit of cancer immunotherapy: a multi-stakeholder perspective.
Quinn C; Garrison LP; Pownell AK; Atkins MB; de Pouvourville G; Harrington K; Ascierto PA; McEwan P; Wagner S; Borrill J; Wu E
J Immunother Cancer; 2020 Jul; 8(2):. PubMed ID: 32661115
[TBL] [Abstract][Full Text] [Related]
2. A review and validation of overall survival extrapolation in health technology assessments of cancer immunotherapy by the National Institute for Health and Care Excellence: how did the initial best estimate compare to trial data subsequently made available?
Bullement A; Meng Y; Cooper M; Lee D; Harding TL; O'Regan C; Aguiar-Ibanez R
J Med Econ; 2019 Mar; 22(3):205-214. PubMed ID: 30422080
[TBL] [Abstract][Full Text] [Related]
3. Development of a framework and decision tool for the evaluation of health technologies based on surrogate endpoint evidence.
Ciani O; Grigore B; Taylor RS
Health Econ; 2022 Sep; 31 Suppl 1(Suppl 1):44-72. PubMed ID: 35608044
[TBL] [Abstract][Full Text] [Related]
4. Health technology assessment of medical devices: What is different? An overview of three European projects.
Schnell-Inderst P; Mayer J; Lauterberg J; Hunger T; Arvandi M; Conrads-Frank A; Nachtnebel A; Wild C; Siebert U
Z Evid Fortbild Qual Gesundhwes; 2015; 109(4-5):309-18. PubMed ID: 26354131
[TBL] [Abstract][Full Text] [Related]
5. Health technology assessment of tests for SARS-CoV-2 and treatments for COVID-19: A proposed approach and best-practice recommendations.
Elvidge J; Summerfield A; Knies S; Németh B; Kaló Z; Goettsch W; Dawoud DM;
Int J Technol Assess Health Care; 2023 Apr; 39(1):e24. PubMed ID: 37092749
[TBL] [Abstract][Full Text] [Related]
6. Challenges in Research and Health Technology Assessment of Rare Disease Technologies: Report of the ISPOR Rare Disease Special Interest Group.
Nestler-Parr S; Korchagina D; Toumi M; Pashos CL; Blanchette C; Molsen E; Morel T; Simoens S; Kaló Z; Gatermann R; Redekop W
Value Health; 2018 May; 21(5):493-500. PubMed ID: 29753344
[TBL] [Abstract][Full Text] [Related]
7. Measuring Survival Benefit in Health Technology Assessment in the Presence of Nonproportional Hazards.
Monnickendam G; Zhu M; McKendrick J; Su Y
Value Health; 2019 Apr; 22(4):431-438. PubMed ID: 30975394
[TBL] [Abstract][Full Text] [Related]
8. Value added medicines: what value repurposed medicines might bring to society?
Toumi M; Rémuzat C
J Mark Access Health Policy; 2017; 5(1):1264717. PubMed ID: 28265347
[No Abstract] [Full Text] [Related]
9. Health technology assessment of medical devices: a survey of non-European union agencies.
Ciani O; Wilcher B; Blankart CR; Hatz M; Rupel VP; Erker RS; Varabyova Y; Taylor RS
Int J Technol Assess Health Care; 2015 Jan; 31(3):154-65. PubMed ID: 26044729
[TBL] [Abstract][Full Text] [Related]
10. Challenges of Conducting Value Assessment for Comprehensive Genomic Profiling.
Tarride JE; Gould T; Thomas DM
Int J Technol Assess Health Care; 2022 Jun; 38(1):e57. PubMed ID: 35674123
[TBL] [Abstract][Full Text] [Related]
11. Assessing the Performance of Alternative Methods for Estimating Long-Term Survival Benefit of Immuno-oncology Therapies.
Monnickendam G
Value Health; 2024 Jun; 27(6):746-754. PubMed ID: 38428815
[TBL] [Abstract][Full Text] [Related]
12. Current Issues in Health Technology Assessment of Cancer Therapies: A Survey of Stakeholders and Opinion Leaders in Australia.
Kim H; Liew D; Goodall S
Int J Technol Assess Health Care; 2022 Jun; 38(1):e49. PubMed ID: 35703423
[TBL] [Abstract][Full Text] [Related]
13. IS THE EUNETHTA HTA CORE MODEL® FIT FOR PURPOSE? EVALUATION FROM AN INDUSTRY PERSPECTIVE.
Gyldmark M; Lampe K; Ruof J; Pöhlmann J; Hebborn A; Kristensen FB
Int J Technol Assess Health Care; 2018 Jan; 34(5):458-463. PubMed ID: 30334508
[TBL] [Abstract][Full Text] [Related]
14. Comparison of Long-term Survival Benefits in Trials of Immune Checkpoint Inhibitor vs Non-Immune Checkpoint Inhibitor Anticancer Agents Using ASCO Value Framework and ESMO Magnitude of Clinical Benefit Scale.
Everest L; Shah M; Chan KKW
JAMA Netw Open; 2019 Jul; 2(7):e196803. PubMed ID: 31290990
[TBL] [Abstract][Full Text] [Related]
15. Models and applications for measuring the impact of health research: update of a systematic review for the Health Technology Assessment programme.
Raftery J; Hanney S; Greenhalgh T; Glover M; Blatch-Jones A
Health Technol Assess; 2016 Oct; 20(76):1-254. PubMed ID: 27767013
[TBL] [Abstract][Full Text] [Related]
16. Building Synergy between Regulatory and HTA Agencies beyond Processes and Procedures-Can We Effectively Align the Evidentiary Requirements? A Survey of Stakeholder Perceptions.
Wang T; McAuslane N; Liberti L; Leufkens H; Hövels A
Value Health; 2018 Jun; 21(6):707-714. PubMed ID: 29909876
[TBL] [Abstract][Full Text] [Related]
17. Health technology assessment in Australia: a role for clinical registries?
Scott AM
Aust Health Rev; 2017 Mar; 41(1):19-25. PubMed ID: 27028134
[TBL] [Abstract][Full Text] [Related]
18. Avoiding and identifying errors in health technology assessment models: qualitative study and methodological review.
Chilcott J; Tappenden P; Rawdin A; Johnson M; Kaltenthaler E; Paisley S; Papaioannou D; Shippam A
Health Technol Assess; 2010 May; 14(25):iii-iv, ix-xii, 1-107. PubMed ID: 20501062
[TBL] [Abstract][Full Text] [Related]
19. Developing a Framework for the Health Technology Assessment of Histology-independent Precision Oncology Therapies.
Gaultney JG; Bouvy JC; Chapman RH; Upton AJ; Kowal S; Bokemeyer C; Solà-Morales O; Wolf J; Briggs AH
Appl Health Econ Health Policy; 2021 Sep; 19(5):625-634. PubMed ID: 34028672
[TBL] [Abstract][Full Text] [Related]
20. How can a joint European health technology assessment provide an 'additional benefit' over the current standard of national assessments? : Insights generated from a multi-stakeholder survey in hematology/oncology.
Julian E; Gianfrate F; Sola-Morales O; Mol P; Bergmann JF; Salmonson T; Hebborn A; Grande M; Ruof J
Health Econ Rev; 2022 Jun; 12(1):30. PubMed ID: 35652987
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
